BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26240051)

  • 1. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
    Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
    Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
    Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
    Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 11. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
    Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
    Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of epigenetics in malignant pleural mesothelioma.
    Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
    Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
    Kato T; Jin CS; Lee D; Ujiie H; Fujino K; Hu HP; Wada H; Wu L; Chen J; Weersink RA; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Wilson BC; Zheng G; Yasufuku K
    Int J Oncol; 2018 Nov; 53(5):2034-2046. PubMed ID: 30226590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
    Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
    Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
    Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
    Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
    Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.